middle.news
Hexima Charts Capital Return and Board Renewal After Clinical Setback
2:31pm on Thursday 27th of November, 2025 AEDT
•
Healthcare
Read Story
Hexima Charts Capital Return and Board Renewal After Clinical Setback
2:31pm on Thursday 27th of November, 2025 AEDT
Key Points
Disappointing clinical trial results ended main development program
Company holds $1.4 million cash and contingent royalty rights
Proposed $1 million capital return subject to shareholder approval
Plans for small-holding buybacks and board composition review
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Hexima (ASX:HXL)
OPEN ARTICLE